Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Payables: 2012-2024

Historic Payables for Veracyte (VCYT) over the last 13 years, with Dec 2024 value amounting to $8.6 million.

  • Veracyte's Payables fell 43.03% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.3 million, marking a year-over-year decrease of 11.85%. This contributed to the annual value of $8.6 million for FY2024, which is 33.29% down from last year.
  • As of FY2024, Veracyte's Payables stood at $8.6 million, which was down 33.29% from $12.9 million recorded in FY2023.
  • In the past 5 years, Veracyte's Payables ranged from a high of $12.9 million in FY2023 and a low of $3.1 million during FY2020.
  • Its 3-year average for Payables is $11.2 million, with a median of $11.9 million in 2022.
  • Its Payables has fluctuated over the past 5 years, first surged by 296.66% in 2021, then slumped by 33.29% in 2024.
  • Yearly analysis of 5 years shows Veracyte's Payables stood at $3.1 million in 2020, then surged by 296.66% to $12.4 million in 2021, then dropped by 3.63% to $11.9 million in 2022, then increased by 8.66% to $12.9 million in 2023, then tumbled by 33.29% to $8.6 million in 2024.